AU2012307336B2 - Methods for monitoring responsiveness to anti-SMAD7 therapy - Google Patents

Methods for monitoring responsiveness to anti-SMAD7 therapy Download PDF

Info

Publication number
AU2012307336B2
AU2012307336B2 AU2012307336A AU2012307336A AU2012307336B2 AU 2012307336 B2 AU2012307336 B2 AU 2012307336B2 AU 2012307336 A AU2012307336 A AU 2012307336A AU 2012307336 A AU2012307336 A AU 2012307336A AU 2012307336 B2 AU2012307336 B2 AU 2012307336B2
Authority
AU
Australia
Prior art keywords
cells
ccr9
foxp3
ifn
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012307336A
Other languages
English (en)
Other versions
AU2012307336A1 (en
Inventor
Salvatore Bellinvia
Giovanni Monteleone
Francesca Viti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nogra Pharma Ltd
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of AU2012307336A1 publication Critical patent/AU2012307336A1/en
Application granted granted Critical
Publication of AU2012307336B2 publication Critical patent/AU2012307336B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Ecology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2012307336A 2011-09-15 2012-09-14 Methods for monitoring responsiveness to anti-SMAD7 therapy Ceased AU2012307336B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11425234 2011-09-15
EP11425234.9 2011-09-15
US201161576556P 2011-12-16 2011-12-16
US61/576,556 2011-12-16
PCT/EP2012/068146 WO2013037970A1 (en) 2011-09-15 2012-09-14 Methods for monitoring responsiveness to anti-smad7 therapy

Publications (2)

Publication Number Publication Date
AU2012307336A1 AU2012307336A1 (en) 2014-03-27
AU2012307336B2 true AU2012307336B2 (en) 2017-08-24

Family

ID=47882658

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012307336A Ceased AU2012307336B2 (en) 2011-09-15 2012-09-14 Methods for monitoring responsiveness to anti-SMAD7 therapy

Country Status (11)

Country Link
US (2) US9791442B2 (enExample)
EP (2) EP2748611B1 (enExample)
JP (1) JP6389122B2 (enExample)
KR (1) KR102099990B1 (enExample)
CN (1) CN104040349B (enExample)
AU (1) AU2012307336B2 (enExample)
CA (1) CA2848595A1 (enExample)
ES (1) ES2617200T3 (enExample)
MX (1) MX350087B (enExample)
RU (1) RU2678450C2 (enExample)
WO (1) WO2013037970A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
NZ592673A (en) 2008-11-13 2013-01-25 Giuliani Int Ltd Antisense compositions with enteric coating for treating crohn's disease, colitis and bowel disease
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
ES2673209T3 (es) * 2013-03-15 2018-06-20 Nogra Pharma Limited Procedimientos de tratamiento del cáncer colorrectal
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
US20160139123A1 (en) * 2013-07-12 2016-05-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Shear Wave Imaging Method and Installation for Collecting Information on a Soft Solid
CN106573065A (zh) 2014-05-09 2017-04-19 诺格尔制药有限公司 用于治疗炎症性肠病的方法
WO2016059239A1 (en) * 2014-10-17 2016-04-21 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
EP3693736A3 (en) * 2014-10-17 2020-10-14 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
MA41271A (fr) * 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
WO2017019673A2 (en) * 2015-07-27 2017-02-02 Genentech, Inc. Methods for diagnosing and treating inflammatory bowel disease
EP3356530A4 (en) * 2015-09-30 2019-04-10 Celgene Alpine Investment Company II, LLC TLR-MODULATORS AND METHOD OF USE
CA3000569A1 (en) * 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression
US11162097B2 (en) 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
US10517889B2 (en) 2017-09-08 2019-12-31 Ionis Pharmaceuticals, Inc. Modulators of SMAD7 expression
US11619832B2 (en) 2018-03-08 2023-04-04 Coopervision International Limited Identification of contact lens wearers predisposed to contact lens discomfort
CN110082538B (zh) * 2019-04-19 2021-12-03 中山大学附属第六医院 CCR9+IL-17+Treg细胞在制备用于检测NEC的试剂盒中的应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6159697A (en) 2000-01-19 2000-12-12 Isis Pharmaceuticals, Inc. Antisense modulation of Smad7 expression
RU2185627C2 (ru) * 2000-09-11 2002-07-20 Новосибирская государственная медицинская академия Способ определения чувствительности (восприимчивости) к внутривенной лазеротерапии больных ишемической болезнью сердца
ES2388968T3 (es) 2001-11-02 2012-10-22 Giuliani International Limited Inhibidores de Smad7 para el tratamiento de enfermedades del SNC
ITRM20030149A1 (it) * 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
US20090275496A1 (en) 2004-05-07 2009-11-05 Peptimmune, Inc. Effective quantitation of complex peptide mixtures in tissue samples and improved therapeutic methods
ES2563955T3 (es) 2005-08-02 2016-03-16 Centenary Institute Of Cancer Medicine & Cell Biology Método para identificar linfocitos T reguladores
AU2007224967A1 (en) * 2006-03-10 2007-09-20 Mount Sinai Hospital Diagnostic compositions and treatment methods for conditions involving trophoblast cell death, differentiation, invasion and/or cell fusion and turnover
EP2167647A2 (en) * 2007-06-13 2010-03-31 La Jolla Institute For Allergy And Immunology Regulatory t cells and methods of making and using same
WO2009107785A1 (ja) 2008-02-28 2009-09-03 シスメックス株式会社 Il-17産生ヘルパーt細胞検出用マーカー及びil-17産生ヘルパーt細胞の検出方法
JP2010051307A (ja) 2008-07-28 2010-03-11 Eisai R & D Management Co Ltd Ｔｈ１７細胞およびＴｒｅｇ細胞の分化誘導を調節する物質のスクリーニング方法
NZ592673A (en) 2008-11-13 2013-01-25 Giuliani Int Ltd Antisense compositions with enteric coating for treating crohn's disease, colitis and bowel disease
CN102483405B (zh) 2009-07-10 2015-12-02 特朗斯吉有限公司 用于选择患者的生物标志物及相关方法
US8766034B2 (en) 2010-09-22 2014-07-01 Cedars-Sinai Medical Center TL1A model of inflammation fibrosis and autoimmunity
CN107252492A (zh) 2012-04-18 2017-10-17 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
ES2673209T3 (es) 2013-03-15 2018-06-20 Nogra Pharma Limited Procedimientos de tratamiento del cáncer colorrectal
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
CN106573065A (zh) 2014-05-09 2017-04-19 诺格尔制药有限公司 用于治疗炎症性肠病的方法
WO2016059239A1 (en) 2014-10-17 2016-04-21 Nogra Pharma Limited Methods and compositions for treating a subject with a smad7 antisense oligonucleotide
EP3693736A3 (en) 2014-10-17 2020-10-14 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
CA3000569A1 (en) 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FANTINI, M. C. et al., Gastroenterology, 2009, vol. 136, pages 1308-1316 *
MONTELEONE, G. et al., J. Clin. Invest., 2001, vol. 108, no. 4, pages 601-609 *

Also Published As

Publication number Publication date
EP2748611A1 (en) 2014-07-02
KR20140059859A (ko) 2014-05-16
US20150148245A1 (en) 2015-05-28
AU2012307336A1 (en) 2014-03-27
RU2014114838A (ru) 2015-10-20
JP6389122B2 (ja) 2018-09-12
US20180128829A1 (en) 2018-05-10
HK1199095A1 (en) 2015-06-19
MX2014003295A (es) 2014-05-28
US9791442B2 (en) 2017-10-17
WO2013037970A1 (en) 2013-03-21
EP2748611B1 (en) 2016-11-23
ES2617200T3 (es) 2017-06-15
EP3165929A2 (en) 2017-05-10
MX350087B (es) 2017-08-24
KR102099990B1 (ko) 2020-04-13
CA2848595A1 (en) 2013-03-21
RU2678450C2 (ru) 2019-01-29
NZ622067A (en) 2016-05-27
CN104040349B (zh) 2017-07-04
NZ719884A (en) 2020-02-28
EP3165929A3 (en) 2017-06-21
JP2014531584A (ja) 2014-11-27
CN104040349A (zh) 2014-09-10

Similar Documents

Publication Publication Date Title
AU2012307336B2 (en) Methods for monitoring responsiveness to anti-SMAD7 therapy
Maugeri et al. Unconventional CD147‐dependent platelet activation elicited by SARS‐CoV‐2 in COVID‐19
Hollerbach et al. Pathogenic lipid‐binding antiphospholipid antibodies are associated with severity of COVID‐19
US20160061824A1 (en) Methods for detecting inflammatory disorders
US20230051905A1 (en) Triaging method using cell free nucleosome levels
Song et al. A cellular census of human peripheral immune cells identifies novel cell states in lung diseases
EP3693736A2 (en) Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
US12360103B2 (en) Blood biomarker for eosinophilic gastrointestinal disorders
US20210207143A1 (en) Methods of Treating Celiac Disease Using SMAD7 Inhibition
Woo et al. CRACR2A-mediated TCR signaling promotes local effector Th1 and Th17 responses
EP3922641A1 (en) Methods for detecting and treating covid patients requiring intensive care
Fang et al. Glycoprotein 96 in peritoneal dialysis effluent-derived extracellular vesicles: A tool for evaluating peritoneal transport properties and inflammatory status
US20180267035A1 (en) Processes for the diagnosis, prognosis and monitoring of the progression of chronic lymphoid leukaemia (cll) and/or of systemic lupus erythematosus (sle) using membrane stim 1
HK1199095B (en) Methods for monitoring responsiveness to anti-smad7 therapy
KR102225039B1 (ko) Cd8+ 메모리 t 세포 매개성 질환의 예방 또는 치료용 약학 조성물
CN115961043A (zh) 与igfbp1或其靶点结合的物质在制备多发性骨髓瘤诊断或治疗产品中的用途
NZ719884B2 (en) Methods for monitoring responsiveness to anti-SMAD7 therapy
NZ622067B2 (en) Methods for monitoring responsiveness to anti-smad7 therapy
Hume et al. Spatial Heterogeneity of Macrophages in the Human Lung
WO2025225410A1 (ja) 肝線維化、肝硬変、及び肝がんの予防又は治療剤、並びに類洞内圧バイオマーカー
Zhu et al. Exosome-derived circITGB1 regulates dendritic cell maturation and cardiac inflammation via miR-342-3p/NFAM1
HK40100515A (en) Triaging method using cell free nucleosome levels
CN118465263A (zh) 肺癌转移的生物标志物及应用、诊断肺癌转移的试剂盒及治疗药物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired